Aug 9, 2019, 01:00 by admin admin

Aug 9, 2019, 01:00 by admin admin

ASAM responded to an RFI regarding challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment.

Aug 9, 2019, 01:00 by admin admin

Today, the American Society of Addiction Medicine (ASAM) submitted comments to the Centers for Medicare & Medicaid Services (CMS) that recommend revisions to the proposed 2019 Medicare Physician Fee Schedule (MPFS) that will improve the delivery of evidence-based addiction medicine to combat the nation’s opioid overdose epidemic.

Aug 9, 2019, 01:00 by admin admin

The Coalition to Stop Opioid Overdose (CSOO) welcomes HIV Alliance as a new member of the coalition. HIV Alliance was formed in 1994 to support individuals living with HIV/AIDS and prevent new HIV infections.

Aug 9, 2019, 01:00 by admin admin

ASAM offered detailed recommendations for addressing the opioid epidemic.

Aug 9, 2019, 01:00 by admin admin

The Journal of Law, Medicine & Ethics has accepted a letter to the editor urging the Accreditation Council for Graduate Medical Education (ACGME) establish a requirement that all residents and fellows who care for patients who use opioids, as well as their core faculty, receive specific training on the treatment of opioid use disorder (OUD).

Aug 9, 2019, 01:00 by admin admin

Dr. Mejzak stressed the importance of strengthening federal parity law enforcement at a roundtable discussion.

Aug 9, 2019, 01:00 by admin admin

On July 3, the American Society of Addiction Medicine (ASAM), American Academy of PAs (AAPA), American Association of Nurse Practitioners (AANP), and American Osteopathic Academy of Addiction Medicine (AOAAM), approved providers of DATA 2000 training, issued a letter to Attorney General Jeff Sessions thanking the Department of Justice (DOJ) for identifying individuals who may be committing opioid-related criminal activity and health care fraud involving patients with addiction and expressing the need to work together so such actions do not have unintended consequences that dissuade clinicians from prescribing buprenorphine and leave patients without treatment should their practitioners’ offices be closed.

Aug 9, 2019, 01:00 by admin admin

ASAM praised the House Appropriations Committee for including full funding for two new critical substance use disorder (SUD) workforce programs in its FY 2020 Labor, Health and Human Services (HHS), Education, and Related Agencies appropriations bill.

Aug 9, 2019, 01:00 by admin admin

On Friday, June 16th, President Trump’s Commission on Combatting Drug Addiction and the Opioid Crisis held a teleconference to discuss the Opioid Commission’s work and included participants from nine national non-profit organizations as well senior members of the Trump administration.

Aug 9, 2019, 01:00 by admin admin

CSOO and MHLG hosted a roundtable discussion with Congressman David Trone to discuss legislative efforts in Congress regarding mental health and addiction.

Aug 9, 2019, 01:00 by admin admin

Today the American Society of Addiction Medicine (ASAM) submitted a letter to the House Committee on Energy and Commerce as it considers legislation to address the opioid misuse, addiction, and overdose epidemic. The letter, submitted to Chairman Greg Walden (R-OR) and Ranking Member Frank Pallone (D-NJ), urges the Committee to approve bills that expand the provision of evidence-based treatment, strengthen America’s addiction treatment infrastructure, and bolster the nation’s addiction treatment workforce.

Aug 9, 2019, 01:00 by admin admin

Updated definition of addiction to explain more fully the complexity of this chronic disease with the intent of driving a bold and comprehensive national response.

Aug 9, 2019, 01:00 by admin admin

ASAM sent letters of support for the Removing Barriers to Medicaid and CHIP Addiction Treatment Act and the Medicaid Coverage for Addiction Recovery Treatment Act. These bills would work to repeal Medicaid Institutions for the Mental Diseases (IMD) exclusion for mental health and substance use disorder residential treatment facilities. 

Aug 9, 2019, 01:00 by admin admin

On May 16, the Food and Drug Administration (FDA) announced its approval Lucemyra, the first non-opioid treatment for management of opioid withdrawal symptoms. Lucemyra (lofexidine hydrochloride) reduces the release of norepinephrine and can be used to lessen the severity of withdrawal symptoms that may occur after the discontinuation of opioid use.

Aug 9, 2019, 01:00 by admin admin

Yngvild Olsen, MD, MPH urged lawmakers to expand access to evidence-based addiction treatment and invest more resources to address the addiction and overdose crisis during today’s House Committee on Oversight and Reform Hearing .

Aug 9, 2019, 01:00 by admin admin

ASAM took the opportunity to advocate for standardization of addiction treatment when MACPAC released its request for information on the Medicaid IMD Additional INFO Act.

Aug 9, 2019, 01:00 by admin admin

The American Society of Addiction Medicine is pleased to hear that The ASAM Criteria was included in today’s discussion about solutions to combat the opioid misuse and overdose crisis. Addressing this public health emergency will require systemic and sustainable changes to our addiction treatment infrastructure and workforce, as well as expanded access to comprehensive, evidenced-based treatment that includes all levels of care. 

Aug 9, 2019, 01:00 by admin admin

Dr. Kelly J. Clark, president of ASAM, participated in a congressional roundtable sponsored by the House Bipartisan Heroin and Opioid Task Force. At the event, she urged lawmakers to make strategic investments in the substance use disorder (SUD) treatment workforce in order to close the addiction treatment gap and ensure the millions of Americans living with SUD are able to receive the care they need.

Aug 9, 2019, 01:00 by admin admin

The Coalition to Stop Opioid Overdose (CSOO) is proud to announce A New PATH (Parents for Addiction Treatment and Healing) as a new member of the coalition. A New PATH works with families, individuals in recovery, healthcare professionals and community leaders to reduce the stigma associated with addictive illness through education and compassionate support and to advocate for therapeutic rather than punitive drug policies.